Similar Papers

Paper Title
Journal
Date
Author
A7.06 Low-dose IL-2 therapy in refractory sle: Insights from a phase I/IIA clinical trial
Jy Humrich ... G Riemekasten
Annals of the Rheumatic Diseases | VOL. 75
Jy Humrich, et. al.Jy Humrich ... G Riemekasten
01 Feb 2016
06.08 Low-dose il-2 therapy in refractory sle: results from a single centre phase i/iia clinical trial
Jens Y Humrich ... Falk Hiepe
Annals of the Rheumatic Diseases | VOL. 76
Jens Y Humrich, et. al.Jens Y Humrich ... Falk Hiepe
01 Mar 2017
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
Caroline Von Spee-Mayer ... Philipp Enghard
Annals of the Rheumatic Diseases | VOL. 75
Caroline Von Spee-Mayer, et. al.Caroline Von Spee-Mayer ... Philipp Enghard
31 Aug 2015
SP0137 Low-Dose IL-2 Therapy in Refractory SLE: Early Insights from a Phase I/IIA Clinical Trial
J.Y Humrich
Annals of the Rheumatic Diseases | VOL. 74
J.Y HumrichJ.Y Humrich
01 Jun 2015
View more papers

More From: Lupus Science & Medicine

Paper Title
Journal
Date
Author
Ultrasonographic assessment of optic nerve: does it help in lupus-induced optic neuropathy?
Amira Elsonbaty ... Abdallah El-Sayed Allam
Lupus Science & Medicine | VOL. 12
Amira Elsonbaty, et. al.Amira Elsonbaty ... Abdallah El-Sayed Allam
20 Jan 2025
EXamining the feasibility of exerCisE to manage symptoms of Lupus (EXCEL): a protocol for a randomised controlled pilot study
Megan Quickfall ... Alex J Wadley
Lupus Science & Medicine | VOL. 12
Megan Quickfall, et. al.Megan Quickfall ... Alex J Wadley
16 Jan 2025
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis
Huqun Li ... Cuilian Guo
Lupus Science & Medicine | VOL. 12
Huqun Li, et. al.Huqun Li ... Cuilian Guo
09 Jan 2025
Interplay of NF-κB and PPAR-γ transcription factors in patients with juvenile systemic lupus erythematosus
Sinem Durmus ... Ozgur Kasapcopur
Lupus Science & Medicine | VOL. 12
Sinem Durmus, et. al.Sinem Durmus ... Ozgur Kasapcopur
08 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.